Evolution Advisers Inc. Makes New Investment in Stryker Co. (NYSE:SYK)

Evolution Advisers Inc. purchased a new position in Stryker Co. (NYSE:SYK) in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 300 shares of the medical technology company’s stock, valued at approximately $89,000.

Other institutional investors also recently made changes to their positions in the company. Bremer Bank National Association lifted its holdings in Stryker by 4.0% during the 4th quarter. Bremer Bank National Association now owns 888 shares of the medical technology company’s stock valued at $266,000 after purchasing an additional 34 shares during the last quarter. Simon Quick Advisors LLC lifted its holdings in Stryker by 3.0% during the 4th quarter. Simon Quick Advisors LLC now owns 1,158 shares of the medical technology company’s stock valued at $347,000 after purchasing an additional 34 shares during the last quarter. Consolidated Portfolio Review Corp lifted its holdings in Stryker by 3.6% during the 4th quarter. Consolidated Portfolio Review Corp now owns 983 shares of the medical technology company’s stock valued at $294,000 after purchasing an additional 34 shares during the last quarter. MBL Wealth LLC lifted its holdings in Stryker by 4.6% during the 4th quarter. MBL Wealth LLC now owns 850 shares of the medical technology company’s stock valued at $255,000 after purchasing an additional 37 shares during the last quarter. Finally, PDS Planning Inc lifted its holdings in Stryker by 3.0% during the 3rd quarter. PDS Planning Inc now owns 1,318 shares of the medical technology company’s stock valued at $360,000 after purchasing an additional 38 shares during the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently issued reports on SYK. Canaccord Genuity Group raised shares of Stryker from a “hold” rating to a “buy” rating and set a $360.00 price target for the company in a report on Wednesday, January 31st. Roth Mkm lifted their price target on shares of Stryker from $345.00 to $348.00 and gave the company a “buy” rating in a report on Wednesday, January 31st. Wells Fargo & Company boosted their target price on shares of Stryker from $336.00 to $364.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 31st. Canaccord Genuity Group raised shares of Stryker from a “hold” rating to a “buy” rating and boosted their target price for the stock from $315.00 to $360.00 in a research note on Wednesday, January 31st. Finally, Evercore ISI boosted their target price on shares of Stryker from $340.00 to $370.00 and gave the stock an “outperform” rating in a research note on Thursday, April 4th. Three investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $340.67.

Insider Activity at Stryker

In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of the firm’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the completion of the transaction, the chief accounting officer now owns 3,675 shares in the company, valued at approximately $1,317,414. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of Stryker stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the transaction, the chief accounting officer now directly owns 3,675 shares of the company’s stock, valued at approximately $1,317,414. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 201,146 shares of Stryker stock in a transaction on Monday, February 5th. The stock was sold at an average price of $342.90, for a total transaction of $68,972,963.40. Following the transaction, the director now directly owns 3,755,128 shares in the company, valued at $1,287,633,391.20. The disclosure for this sale can be found here. Insiders sold a total of 212,109 shares of company stock worth $72,845,768 in the last quarter. 5.90% of the stock is owned by insiders.

Stryker Trading Up 0.1 %

NYSE SYK traded up $0.24 during trading on Thursday, reaching $337.09. 1,615,335 shares of the stock traded hands, compared to its average volume of 1,286,429. The firm has a market cap of $128.25 billion, a price-to-earnings ratio of 40.86, a price-to-earnings-growth ratio of 2.70 and a beta of 0.89. The stock’s 50-day moving average price is $349.16 and its 200 day moving average price is $314.40. Stryker Co. has a fifty-two week low of $249.98 and a fifty-two week high of $361.41. The company has a quick ratio of 0.97, a current ratio of 1.58 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share for the quarter, beating analysts’ consensus estimates of $3.27 by $0.19. Stryker had a net margin of 15.44% and a return on equity of 22.99%. The company had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. During the same period last year, the company posted $3.00 EPS. The firm’s quarterly revenue was up 11.8% compared to the same quarter last year. Analysts predict that Stryker Co. will post 11.86 EPS for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be issued a $0.80 dividend. The ex-dividend date is Wednesday, March 27th. This represents a $3.20 dividend on an annualized basis and a yield of 0.95%. Stryker’s dividend payout ratio (DPR) is presently 38.79%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.